Biosimilars-why terminology matters

Nature Biotechnology

Volumn 29, Issue 8, 2011, Pages 690-693

  Weise, Martina ^a,j   Bielsky, Marie Christine ^b,j   De Smet, Karen ^c,j   Ehmann, Falk ^d   Ekman, Niklas ^e,j   Narayanan, Gopalan ^b,j   Heim, Hans Karl ^a,j   Heinonen, Esa ^e,j   Ho, Kowid ^f,j   Thorpe, Robin ^g,j   Vleminckx, Camille ^d   Wadhwa, Meenu ^g,j   Schneider, Christian K ^h,i,j  

^a Bundesinstitut fur Arzneimittel und Medizinprodukte BfArM   (Germany)

^b MEDICINES AND HEALTHCARE PRODUCTS REGULATORY AGENCY   (United Kingdom)

^c Federal Agency for Medicines and Health Products Belgium   (Belgium)

^d EUROPEAN MEDICINES AGENCY   (United Kingdom)

^e Finnish Medicines Agency   (Finland)

^f AFSSAPS   (France)

^g NATIONAL INSTITUTE FOR BIOLOGICAL STANDARDS AND CONTROL   (United Kingdom)

^h PAUL EHRLICH INSTITUT   (Germany)

ⁱ INSTITUTE OF INFECTION IMMUNOLOGY   (Germany)

^j EMA ^*  (United Kingdom)

more..

Author keywords

[No Author keywords available]

Indexed keywords

BIOSIMILAR MEDICINAL PRODUCT; BOTULINUM TOXIN; LOW MOLECULAR WEIGHT HEPARIN; PLANT MEDICINAL PRODUCT; RECOMBINANT ERYTHROPOIETIN; RECOMBINANT PROTEIN; UNCLASSIFIED DRUG;

CHEMICAL ANALYSIS; DRUG DOSE REGIMEN; DRUG EFFICACY; DRUG FORMULATION; DRUG MANUFACTURE; DRUG MARKETING; DRUG SAFETY; DRUG SCREENING; EUROPEAN UNION; FOOD AND DRUG ADMINISTRATION; HUMAN; LETTER; NONHUMAN; PHYSICAL CHEMISTRY; PRIORITY JOURNAL;

BIOSIMILAR PHARMACEUTICALS; CLINICAL TRIALS AS TOPIC; DRUG APPROVAL; HUMANS; TERMINOLOGY AS TOPIC; THERAPEUTIC EQUIVALENCY;

EID: 79961203419     PISSN: 10870156     EISSN: 15461696     Source Type: Journal    
DOI: 10.1038/nbt.1936     Document Type: Letter

References (19)

1. Regulation (EC) 726/2004 of the European Parliament and of the Council. Official J. EU L136/1-L136/33 (2004).
2. Committee for Medicinal Products for Human Use. Biosimilar Guidelines (accessed 20 July 2011); 〈http://www.ema.europa.eu/htms/human/ humanguidelines/multidiscipline.htm〉
3. European Commission. Directive 2001/83/EC Art. 10(4) and Part II of the Annex I of Directive 2001/83/EC, as amended. EudraLex, Volume 1, Pharmaceutical legislation medicinal products for human use (accessed 20 July 2011); 〈http://ec.europa.eu/health/files/eudralex/vol-1/dir-2001-83-cons2009/ 2001-83-cons2009-en.pdf〉
4. European Medicines Agency. Guideline on Comparability of Biotechnology-Derived Medicinal Products After a Change in the Manufacturing Process: Non-Clinical and Clinical Issues EMEA/CHMP/BMWP/101695/2006 (EMA, London, 19 July 2007; accessed 20 July 2011) 〈http://www.ema.europa.eu/ docs/en-GB/document-library/Scientific-guideline/2009/09/WC500003935. pdf〉
5. Chirino, A.J. & Mire-Sluis, A. Nat. Biotechnol. 22, 1383-1391 (2004).
6. Schellekens, H. NDT Plus 2 (suppl. 1), i27-i36 (2009).
7. Brockmeyer, C. & Seidl, A. EJHPPract. 15, 38-44 (2009).
8. European Medicines Agency. EPARs for authorised medicinal products for human use (accessed 20 July 2011); 〈http://www.ema.europa.eu/ema/index.jsp? curl=pages/medicines/landing/epar-search.jsp&murl=menus/medicines/medicines. jsp&mid=WC0b01ac058001d125〉
9. Combe, C., Tredree, R.L. & Schellekens, H. Pharmacotherapy 25, 954-962 (2005).
10. Schmidt, C.A., Ramos, A.S., da Silva, J.E.P., Fronza, M. & Dalmora, S.L. Arq. Bras. Endocrinol. Metabol. 47, 183-189 (2003).
11. Keithi-Reddy, S.R., Kandasamy, S. & Singh, A.K. Kidney Int. 74, 1617-1622 (2008).
12. Gray, E. & Mulloy, B. J. Thromb. Haemost. 7, 1218-1221 (2009).
13. Wenzel, R.G. Am. J. Health Syst. Pharm. 65 (suppl. 6), S9-S15 (2008).
14. World Health Organization. General information on counterfeit medicines (accessed 20 July 2011) 〈http://www.who.int/medicines/services/counterfeit/ overview/en/〉
15. Fotiou, F., Aravind, S., Wang, P.P. & Nerapusee, O. Clin. Ther. 31, 336-346 (2009).
16. Anonymous. Aids Alert 18, 79-80 (2003).
17. World Health Organization. Expert Committee on Biological Standardization. Guidelines on Evaluation of Similar Biotherapeutic Products (WHO, Geneva, 2009; accessed 20 July 2011) 〈http://www. who.int/biologicals/areas/biological-therapeutics/BIOTHERAPEUTICS-FOR-WEB- 22APRIL2010. pdf〉.
18. Federal Drug Administration. Follow-on protein products: regulatory and scientific issues related to developing (accessed 31 May 2011) 〈http://www.fda.gov/Drugs/ScienceResearch/ResearchAreas/ucm085854.htm〉
19. Patient Protection and Affordable Care Act, as amended by the 111th Congress, H.R.3590 (accessed 20 July 2011). 〈http://frwebgate.access.gpo. gov/cgi-bin/getdoc. cgi?dbname=111-cong-bills&docid=f:h3590enr.txt. pdf〉